Rising incidences of cancer, increasing investment and funding, and advancements in nuclear medicine boost the global radioligand therapy (RLT) market growth at a CAGR of 9.41% during the forecast period 2023 to 2030.

Market Research Future (MRFR) has published a cooked research report on the “global radioligand therapy (RLT) market” that contains information from 2019 to 2030. The radioligand therapy (RLT) market is attributed to register a CAGR of 9.41% during the forecast period of 2023 to 2030.

MRFR recognizes the following companies as the key players in the global radioligand therapy (RLT) market— Novartis AG (Switzerland), POINT Biopharma Global Inc. (US), Molecular Partners (Switzerland), Telix Pharmaceuticals Limited (Australia), Fusion Pharma (US), Lantheus Holdings, Inc. (US), Curium (France), Precrix (Belgium), Orano Group (Paris), Artios Pharma (UK) and others.

Market Highlights

The global radioligand therapy (RLT) market is estimated to register a CAGR of 9.41% during the forecast period and is projected to reach USD 13.97 billion by 2030.

The market is expanding due to factors such as rising cancer incidences, an increase in the number of product launches & pipeline products, increasing investment & funding, and advancements in nuclear medicine. Furthermore, the trends creating huge awareness for market growth are current developments in nuclear medicine and radioactive isotopes, including new & cost-effective ways to produce large amounts of medically useful radioactive isotopes.

However, the side effects of radioligand therapy and the unavailability of buildings and infrastructure needed to perform radioligand therapy in developing regions are limiting the market's growth. Moreover, there will be a growing number of product launches and pipeline product opportunities for the market during the forecast period. Additionally, as per the National Institute for Health and Care Research (UK) research, the majority of research and development is concentrated on suitable PET radioligand technologies, which is a lucrative opportunity for market growth.

Access full report @ https://www.marketresearchfuture.com/reports/radioligand-therapy-rlt-market-11824

Segment Analysis

The global radioligand therapy (RLT) market has been segmented based on isotope, targeted receptor, indication, and end user.

On the basis of isotope, the market is segmented into fluorine – 18, gallium – 68, lutetium – 177, and others including actinium-225 and iodine-131. The fluorine-18 segment held the largest market share in 2022 due to the wide range of applications of fluorine-18 in diagnosing cancer. Moreover, lutetium-177 is the fastest-growing segment due to the increasing production of this isotope in the countries of Europe and Asia-Pacific by Novartis AG (Switzerland) in order to fulfill the demand of physicians and patients.

Based on targeted receptor, the global radioligand therapy (RLT) market has been segmented into prostate-specific membrane antigen (PSMA), somatostatin receptor (SSTR), epidermal growth factor receptor (EGFR), and others including gastrin-releasing peptide receptor (GRPR) and human epidermal growth factor receptor 2 (HER2). The prostate-specific membrane antigen (PSMA) segment dominated the market in 2022 and is the fastest-growing segment during the forecast period. This is due to the heavy indulgence of some giant players, including Novartis AG (Switzerland) and Molecular Partners (Switzerland) in developing radioligand for the target receptor namely PSMA.

The global radioligand therapy (RLT) market, based on indication, has been segmented into prostate cancer, neuroendocrine tumors (NETs), breast cancer, and others including lymphoma and non-Hodgkin’s, lymphoma, lung cancer, pancreatic cancer, and atherosclerosis. The prostate cancer segment held the largest market share in 2022 and NETs is the fastest-growing segment during the forecast period, i.e., 2023 to 2030. This is due to the increasing prevalence of prostate cancer and utilizes in the diagnosis & treatment of prostate cancer, especially metastatic castration-resistant prostate cancer (mCRPC).

On the basis of end user, the global radioligand therapy (RLT) market has been segmented into hospitals & clinics, diagnostic centers, and others including ambulatory surgical centers and research & academic institutes. Hospital & clinics accounted for the largest market share and diagnostic centers is the fastest-growing segment during the forecast period owing to the increasing prevalence of cancer and growing facilities for radioligand therapies in diagnostic centers and hospitals in regions such as North America and Europe.

Regional Analysis

The global radioligand therapy (RLT) market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The Europe radioligand therapy (RLT) market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The radioligand therapy (RLT) market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the World radioligand therapy (RLT) market comprises the Middle East, Africa, and Latin America.

The North America radioligand therapy (RLT) market held the largest market share in 2022 due to factors such as the increasing incidences of chronic diseases, the presence of major players, and growing clinical trials based on radioligand. As per the National Institute for Health and Care Research Innovation Observatory (NIHRIO), there were 11 clinical trials ongoing associated with radioligand therapy until May 2021, of which the US is one of the major countries included. 

Furthermore, the Europe radioligand therapy (RLT) market shows significant growth during the forecast period. This is due to the increasing prevalence of prostate cancer, the active presence of giant players, and the increase in the production of radioligand products in the region. For instance, in May 2022, Novartis AG (Switzerland) announced the voluntary suspension of the production of radioligand therapy at Ivrea, Italy. Moreover, as per the European Commission, prostate cancer accounted for 23.2% of all the new cases diagnosed except skin cancer in 2020.  

Moreover, the factors influencing the growth of the Asia-Pacific radioligand therapy (RLT) market are the growing aging population and the rising incidences of cancer. Moreover, the increasing penetration of radioligand manufacturers, including Novartis AG, in the Asia-Pacific region for the bulk production of the radioligand product is creating huge opportunities for the region’s market growth.

Also, the Middle East, Africa, and Latin America regions comprised the rest of the world. The region accounted for the lowest market share in the radioligand therapy (RLT) market due to a lack of awareness associated with therapy and the lack of hospital infrastructure for the therapy.

Key Findings of the Study

• The global radioligand therapy (RLT) market is expected to reach USD 13.97 billion by 2030, at a CAGR of 9.41% during the forecast period.


• The Europe region shows significant growth during the forecast period due to the presence of major players and favorable government support for the approval of radioligand therapy.


• Based on targeted receptor, the prostate-specific membrane antigen (PSMA) segment held the largest market share in 2022, with an approximate market share of 45% to 55%.


• Novartis AG (Switzerland), POINT Biopharma Global Inc. (US), Molecular Partners (Switzerland), Telix Pharmaceuticals Limited (Australia), Fusion Pharma (US), Lantheus Holdings, Inc. (US), Curium (France), Precrix (Belgium), Orano Group (Paris), and Artios Pharma (UK) and others are the key market players.